Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function

Ajit S. Narang, Omaima Sabek, Ahmed O. Gaber, Ram I. Mahato

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose. Ex vivo gene therapy approaches can improve the outcome of islet transplantation for treating type I diabetes. We have previously shown the improvement in islet function and vascularization following ex vivo transfection for human vascular endothelial growth factor (hVEGF) gene expression. In this study, we tested the hypothesis that co-expression of two genes, which target different challenges faced by islets post-transplantation, supplement each other to improve the survival and function of islets. We determined whether there is an additive effect of hVEGF and human interleukin-1 receptor antagonist (hIL-1Ra) gene expression in human islets. Materials and Methods. Human islets were co-infected with adenoviral vectors encoding hVEGF and hIL-1Ra. Islets were then incubated with a cocktail of inflammatory cytokines (IL-1β + TNFα + IFNγ), and islet viability and function were determined. In vivo function was evaluated by transplanting islets under the kidney capsules of streptozotocin-induced non-obese diabetic severe combined immunodeficient (NOD-SCID) mice. Results. Infection of human islets with Adv-hVEGF and/or Adv-hIL-1Ra inhibited expression of inducible nitric oxide synthase (iNOS), decreased the production of nitric oxide (NO), and prevented the loss of in vitro glucose-stimulated insulin response and viability. Moreover, co-expression of hVEGF and hIL-1Ra reduced the blood glucose level of mice, and increased the level of blood insulin and c-peptide upon glucose challenge. Conclusions. Our results indicated that co-expression of genes that target different insults to transplanted islets can improve the outcome of islet transplantation better than either gene alone.

Original languageEnglish (US)
Pages (from-to)1970-1982
Number of pages13
JournalPharmaceutical Research
Volume23
Issue number9
DOIs
StatePublished - Sep 1 2006

Fingerprint

Interleukin-1 Receptors
Vascular Endothelial Growth Factor A
Survival
Islets of Langerhans Transplantation
Genes
Gene expression
Gene Expression
Insulin
Glucose
Gene therapy
Nitric Oxide Synthase Type II
Streptozocin
Medical problems
Interleukin-1
Capsules
Inbred NOD Mouse
Blood Glucose
SCID Mice
Nitric Oxide
Blood

Keywords

  • Adenovirus
  • Diabetes
  • Gene therapy
  • Interleukin-1 receptor antagonist
  • Transplantation
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function. / Narang, Ajit S.; Sabek, Omaima; Gaber, Ahmed O.; Mahato, Ram I.

In: Pharmaceutical Research, Vol. 23, No. 9, 01.09.2006, p. 1970-1982.

Research output: Contribution to journalArticle

@article{2284c255c0e74e5c99d9ffeec2b5508e,
title = "Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function",
abstract = "Purpose. Ex vivo gene therapy approaches can improve the outcome of islet transplantation for treating type I diabetes. We have previously shown the improvement in islet function and vascularization following ex vivo transfection for human vascular endothelial growth factor (hVEGF) gene expression. In this study, we tested the hypothesis that co-expression of two genes, which target different challenges faced by islets post-transplantation, supplement each other to improve the survival and function of islets. We determined whether there is an additive effect of hVEGF and human interleukin-1 receptor antagonist (hIL-1Ra) gene expression in human islets. Materials and Methods. Human islets were co-infected with adenoviral vectors encoding hVEGF and hIL-1Ra. Islets were then incubated with a cocktail of inflammatory cytokines (IL-1β + TNFα + IFNγ), and islet viability and function were determined. In vivo function was evaluated by transplanting islets under the kidney capsules of streptozotocin-induced non-obese diabetic severe combined immunodeficient (NOD-SCID) mice. Results. Infection of human islets with Adv-hVEGF and/or Adv-hIL-1Ra inhibited expression of inducible nitric oxide synthase (iNOS), decreased the production of nitric oxide (NO), and prevented the loss of in vitro glucose-stimulated insulin response and viability. Moreover, co-expression of hVEGF and hIL-1Ra reduced the blood glucose level of mice, and increased the level of blood insulin and c-peptide upon glucose challenge. Conclusions. Our results indicated that co-expression of genes that target different insults to transplanted islets can improve the outcome of islet transplantation better than either gene alone.",
keywords = "Adenovirus, Diabetes, Gene therapy, Interleukin-1 receptor antagonist, Transplantation, Vascular endothelial growth factor",
author = "Narang, {Ajit S.} and Omaima Sabek and Gaber, {Ahmed O.} and Mahato, {Ram I.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1007/s11095-006-9065-7",
language = "English (US)",
volume = "23",
pages = "1970--1982",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function

AU - Narang, Ajit S.

AU - Sabek, Omaima

AU - Gaber, Ahmed O.

AU - Mahato, Ram I.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Purpose. Ex vivo gene therapy approaches can improve the outcome of islet transplantation for treating type I diabetes. We have previously shown the improvement in islet function and vascularization following ex vivo transfection for human vascular endothelial growth factor (hVEGF) gene expression. In this study, we tested the hypothesis that co-expression of two genes, which target different challenges faced by islets post-transplantation, supplement each other to improve the survival and function of islets. We determined whether there is an additive effect of hVEGF and human interleukin-1 receptor antagonist (hIL-1Ra) gene expression in human islets. Materials and Methods. Human islets were co-infected with adenoviral vectors encoding hVEGF and hIL-1Ra. Islets were then incubated with a cocktail of inflammatory cytokines (IL-1β + TNFα + IFNγ), and islet viability and function were determined. In vivo function was evaluated by transplanting islets under the kidney capsules of streptozotocin-induced non-obese diabetic severe combined immunodeficient (NOD-SCID) mice. Results. Infection of human islets with Adv-hVEGF and/or Adv-hIL-1Ra inhibited expression of inducible nitric oxide synthase (iNOS), decreased the production of nitric oxide (NO), and prevented the loss of in vitro glucose-stimulated insulin response and viability. Moreover, co-expression of hVEGF and hIL-1Ra reduced the blood glucose level of mice, and increased the level of blood insulin and c-peptide upon glucose challenge. Conclusions. Our results indicated that co-expression of genes that target different insults to transplanted islets can improve the outcome of islet transplantation better than either gene alone.

AB - Purpose. Ex vivo gene therapy approaches can improve the outcome of islet transplantation for treating type I diabetes. We have previously shown the improvement in islet function and vascularization following ex vivo transfection for human vascular endothelial growth factor (hVEGF) gene expression. In this study, we tested the hypothesis that co-expression of two genes, which target different challenges faced by islets post-transplantation, supplement each other to improve the survival and function of islets. We determined whether there is an additive effect of hVEGF and human interleukin-1 receptor antagonist (hIL-1Ra) gene expression in human islets. Materials and Methods. Human islets were co-infected with adenoviral vectors encoding hVEGF and hIL-1Ra. Islets were then incubated with a cocktail of inflammatory cytokines (IL-1β + TNFα + IFNγ), and islet viability and function were determined. In vivo function was evaluated by transplanting islets under the kidney capsules of streptozotocin-induced non-obese diabetic severe combined immunodeficient (NOD-SCID) mice. Results. Infection of human islets with Adv-hVEGF and/or Adv-hIL-1Ra inhibited expression of inducible nitric oxide synthase (iNOS), decreased the production of nitric oxide (NO), and prevented the loss of in vitro glucose-stimulated insulin response and viability. Moreover, co-expression of hVEGF and hIL-1Ra reduced the blood glucose level of mice, and increased the level of blood insulin and c-peptide upon glucose challenge. Conclusions. Our results indicated that co-expression of genes that target different insults to transplanted islets can improve the outcome of islet transplantation better than either gene alone.

KW - Adenovirus

KW - Diabetes

KW - Gene therapy

KW - Interleukin-1 receptor antagonist

KW - Transplantation

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33750591089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750591089&partnerID=8YFLogxK

U2 - 10.1007/s11095-006-9065-7

DO - 10.1007/s11095-006-9065-7

M3 - Article

C2 - 16906455

AN - SCOPUS:33750591089

VL - 23

SP - 1970

EP - 1982

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 9

ER -